(Total Views: 629)
Posted On: 06/05/2022 12:28:22 PM
Post# of 154185
MGK, I believe you are misreading the results (or I am).
When they write leronlimab has potent antitumor activity with improved 1 year progression free (PFS) & overall survival (OS)..." they don't mean they attained a year PFS. They mean the PFS as calculate AT ONE YEAR was improved.
The results section includes this:
"At 12 mos, pts had a mPFS = 3.8 mos (95%CI 2.3-6.2) and mOS = 6.6 mos (CI95% 4.9-12+). However, pts treated with 525-700 mg doses (n = 19) had a > 75% improved mPFS = 6.1 mos (95%CI 2.3-7.5) and mOS 12+ mos (95%CI 5.5-12+)."
So the best results were a mPFS of 6.1 mos. and an mOS of 12+ mos.
These are the numbers we've heard before.
When they write leronlimab has potent antitumor activity with improved 1 year progression free (PFS) & overall survival (OS)..." they don't mean they attained a year PFS. They mean the PFS as calculate AT ONE YEAR was improved.
The results section includes this:
"At 12 mos, pts had a mPFS = 3.8 mos (95%CI 2.3-6.2) and mOS = 6.6 mos (CI95% 4.9-12+). However, pts treated with 525-700 mg doses (n = 19) had a > 75% improved mPFS = 6.1 mos (95%CI 2.3-7.5) and mOS 12+ mos (95%CI 5.5-12+)."
So the best results were a mPFS of 6.1 mos. and an mOS of 12+ mos.
These are the numbers we've heard before.
(7)
(0)
